This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
immune response | 1377 |
immune responses | 1227 |
immune system | 541 |
innate immune | 503 |
gene expression | 459 |
class i | 415 |
results suggest | 398 |
dendritic cells | 382 |
inflammatory response | 329 |
infectious diseases | 312 |
cell responses | 311 |
type i | 308 |
dna vaccines | 307 |
present study | 295 |
influenza virus | 294 |
dna vaccine | 278 |
research funds | 268 |
mg kg | 266 |
virus infection | 265 |
public health | 257 |
septic shock | 255 |
epithelial cells | 237 |
adaptive immune | 236 |
cell surface | 233 |
peripheral blood | 232 |
antibody responses | 218 |
important role | 215 |
cytokine production | 206 |
clinical trials | 201 |
disaster response | 197 |
mhc class | 193 |
bone marrow | 192 |
cell lines | 192 |
cell activation | 186 |
respiratory syndrome | 186 |
infected cells | 185 |
vaccine development | 185 |
necrosis factor | 182 |
cd cd | 180 |
graduate school | 180 |
immune cells | 180 |
innate immunity | 180 |
infectious disease | 179 |
inflammatory cytokines | 176 |
host response | 171 |
lymph nodes | 170 |
nervous system | 166 |
delivery systems | 163 |
cell death | 162 |
data suggest | 161 |
pg ml | 160 |
like receptor | 160 |
vaccine delivery | 160 |
results indicate | 158 |
flow cytometry | 157 |
amino acid | 153 |
cell types | 153 |
animal models | 151 |
transcription factor | 148 |
cell line | 148 |
tumor necrosis | 148 |
acute respiratory | 147 |
high levels | 146 |
cell receptor | 145 |
antibody response | 143 |
plasmid dna | 143 |
cell proliferation | 142 |
disaster management | 142 |
antigen presentation | 141 |
cell response | 139 |
viral infection | 138 |
fatty acids | 138 |
host immune | 136 |
may also | 136 |
protective immunity | 135 |
presenting cells | 135 |
specific cd | 132 |
ng ml | 132 |
neutralizing antibodies | 130 |
oxidative stress | 128 |
influenza vaccine | 128 |
nitric oxide | 127 |
mast cells | 126 |
signaling pathways | 123 |
significantly higher | 123 |
monoclonal antibodies | 122 |
dna vaccination | 122 |
organ failure | 121 |
cellular immune | 120 |
public sentiment | 119 |
adhesion molecules | 119 |
viral replication | 118 |
mononuclear cells | 117 |
class ii | 114 |
live attenuated | 114 |
significantly reduced | 114 |
significantly increased | 114 |
cd cells | 114 |
may contribute | 114 |
endothelial cells | 113 |
recent studies | 113 |
molecular mechanisms | 110 |
monoclonal antibody | 109 |
lymph node | 109 |
viral infections | 109 |
deficient mice | 108 |
united states | 108 |
severe acute | 107 |
cord uid | 107 |
doc id | 107 |
protein kinase | 106 |
signal transduction | 106 |
mrna expression | 105 |
dependent manner | 105 |
control group | 105 |
mouse model | 104 |
delivery system | 104 |
inflammatory responses | 104 |
like receptors | 104 |
binding protein | 103 |
th cells | 102 |
stress response | 102 |
wild type | 100 |
central nervous | 99 |
specific immune | 99 |
proinflammatory cytokines | 98 |
amino acids | 97 |
adaptive immunity | 96 |
endoplasmic reticulum | 96 |
nk cells | 96 |
transgenic mice | 95 |
i ifn | 95 |
humoral immune | 92 |
specific ctl | 91 |
may play | 91 |
syncytial virus | 90 |
antigen presenting | 90 |
spinal cord | 90 |
mucosal immune | 89 |
respiratory tract | 89 |
respiratory syncytial | 89 |
dendritic cell | 89 |
i molecules | 88 |
growth factor | 88 |
vaccinia virus | 88 |
mediated immune | 87 |
virus infections | 86 |
previous studies | 86 |
ctl response | 85 |
nkt cells | 84 |
results show | 84 |
immunodeficiency virus | 82 |
acute phase | 81 |
progenitor cells | 81 |
multiple organ | 80 |
i interferon | 80 |
clinical trial | 80 |
findings suggest | 80 |
neonatal sepsis | 80 |
rheumatoid arthritis | 80 |
virus replication | 80 |
ctl responses | 79 |
er stress | 79 |
national institute | 78 |
spleen cells | 77 |
may lead | 77 |
inflammatory diseases | 77 |
transcription factors | 77 |
target cells | 76 |
protein expression | 76 |
phase i | 75 |
blood samples | 75 |
septic patients | 75 |
inflammatory mediators | 75 |
critical role | 75 |
airway epithelium | 74 |
natural killer | 73 |
tissue damage | 73 |
taken together | 73 |
host cells | 73 |
surface expression | 73 |
mechanisms underlying | 72 |
based vaccines | 72 |
blood mononuclear | 72 |
infected mice | 72 |
expression levels | 71 |
antiviral response | 71 |
time points | 71 |
ex vivo | 71 |
antibody titers | 71 |
reactive oxygen | 70 |
protective immune | 70 |
lung injury | 70 |
host defense | 70 |
tumor cells | 70 |
dna damage | 70 |
side effects | 68 |
syndrome coronavirus | 68 |
host cell | 68 |
vaccine adjuvants | 67 |
airway epithelial | 67 |
heat shock | 67 |
human immunodeficiency | 67 |
also observed | 67 |
specific antibodies | 67 |
positive cells | 67 |
mediated immunity | 66 |
hla class | 66 |
neuronal activity | 66 |
plasma membrane | 65 |
severe sepsis | 65 |
significant increase | 65 |
plasma cells | 65 |
purkinje cells | 65 |
cell cycle | 65 |
cgas sting | 65 |
significantly decreased | 65 |
infected patients | 65 |
receptor antagonist | 65 |
hippocampal neurons | 64 |
mycobacterium tuberculosis | 64 |
viral proteins | 64 |
stem cells | 64 |
research institute | 64 |
immune function | 63 |
clinical studies | 63 |
large number | 63 |
significant differences | 63 |
knockout mice | 63 |
mast cell | 63 |
herpes simplex | 63 |
cerebral cortex | 63 |
neutralizing antibody | 62 |
brain science | 62 |
intensive care | 62 |
airway inflammation | 62 |
vaccine antigens | 62 |
cell epitopes | 62 |
cytosolic dna | 62 |
prefrontal cortex | 62 |
gene delivery | 62 |
molecular patterns | 61 |
also found | 61 |
higher levels | 61 |
infl ammatory | 61 |
molecular weight | 61 |
antigen processing | 61 |
two groups | 60 |
cell population | 60 |
cellular responses | 60 |
cell subsets | 60 |
hiv infection | 60 |
subunit vaccines | 59 |
virus type | 59 |
simplex virus | 59 |
healthy volunteers | 59 |
inflammatory cytokine | 59 |
ifn response | 59 |
cell development | 58 |
cellular immunity | 58 |
whole blood | 58 |
university school | 58 |
surface antigen | 58 |
cells expressing | 58 |
protein synthesis | 58 |
blood flow | 58 |
visual cortex | 57 |
multiple sclerosis | 57 |
key role | 57 |
escherichia coli | 57 |
emergency management | 57 |
situ hybridization | 57 |
cell culture | 57 |
mrna levels | 57 |
preterm infants | 57 |
plasma levels | 57 |
fatty acid | 56 |
cell populations | 56 |
also known | 56 |
recognition receptors | 56 |
inkt cells | 56 |
effector cells | 56 |
animal model | 56 |
ko mice | 56 |
specific antibody | 56 |
cell membrane | 55 |
crucial role | 55 |
autoimmune diseases | 55 |
data indicate | 55 |
synaptic transmission | 55 |
cell adhesion | 54 |
healthy controls | 54 |
middle east | 54 |
increased expression | 54 |
cell type | 54 |
ebola virus | 54 |
previously reported | 54 |
protein antigens | 54 |
vaccine formulations | 54 |
days post | 54 |
cell clones | 54 |
increased risk | 54 |
response strategies | 54 |
systemic inflammatory | 53 |
cell differentiation | 53 |
high affinity | 53 |
associated molecular | 53 |
epithelial cell | 53 |
pattern recognition | 53 |
analysis revealed | 53 |
drug delivery | 53 |
significant difference | 53 |
organ dysfunction | 53 |
gene products | 53 |
serum levels | 53 |
nuclear factor | 52 |
immune activation | 52 |
chronic inflammatory | 52 |
viral load | 52 |
pandemic response | 52 |
western blot | 52 |
determine whether | 52 |
different types | 52 |
adhesion molecule | 52 |
respiratory distress | 52 |
systems biology | 52 |
vaccine efficacy | 52 |
influenza vaccines | 52 |
blood pressure | 52 |
infected individuals | 52 |
results demonstrate | 52 |
mutant mice | 52 |
nk cell | 51 |
university graduate | 51 |
mucosal immunity | 51 |
mice showed | 51 |
like particles | 51 |
smooth muscle | 51 |
critically ill | 51 |
rna viruses | 50 |
nucleic acid | 50 |
central role | 50 |
factors influencing | 50 |
vg vd | 50 |
maternal antibodies | 50 |
kyoto university | 50 |
increased levels | 50 |
osaka univ | 50 |
mice immunized | 50 |
producing cells | 50 |
results showed | 50 |
stress responses | 49 |
wide range | 49 |
risk factors | 49 |
social distancing | 49 |
reactive protein | 49 |
based vaccine | 49 |
virus vaccine | 49 |
west nile | 49 |
significantly lower | 49 |
bl mice | 49 |
poorly understood | 49 |
neural stem | 49 |
dna encoding | 48 |
draining lymph | 48 |
health care | 48 |
first time | 48 |
type mice | 48 |
previously shown | 48 |
signaling pathway | 48 |
recent years | 48 |
genes involved | 48 |
th responses | 48 |
cd expression | 48 |
immune cell | 48 |
onset sepsis | 48 |
oxygen species | 48 |
apoptotic cells | 48 |
differentially expressed | 48 |
synaptic plasticity | 47 |
seasonal influenza | 47 |
infectious agents | 47 |
chronic inflammation | 47 |
east respiratory | 47 |
mucosal vaccines | 47 |
stranded rna | 47 |
cortical neurons | 47 |
studies using | 47 |
two different | 47 |
antigen delivery | 47 |
humoral immunity | 47 |
treated mice | 47 |
cell function | 46 |
viral rna | 46 |
major histocompatibility | 46 |
host responses | 46 |
time course | 46 |
activated protein | 46 |
bacterial infections | 46 |
healthy individuals | 46 |
physical activity | 46 |
medical school | 46 |
healthy subjects | 46 |
th th | 46 |
nile virus | 46 |
influenza vaccination | 46 |
lymphoid tissues | 46 |
skeletal muscle | 46 |
cytokine storm | 46 |
disease virus | 46 |
adverse events | 46 |
immune complexes | 46 |
protective effect | 46 |
cytokine levels | 46 |
body weight | 46 |
stimulating factor | 45 |
control mice | 45 |
viral vectors | 45 |
type ii | 45 |
gene therapy | 45 |
recent study | 45 |
synthetic peptides | 45 |
protective efficacy | 45 |
yellow fever | 45 |
long term | 45 |
mental health | 45 |
adrenergic receptor | 45 |
emergency response | 45 |
phase iii | 45 |
nucleic acids | 45 |
growth factors | 45 |
systematic review | 44 |
fold increase | 44 |
protein levels | 44 |
glial cells | 44 |
disease susceptibility | 44 |
mechanisms involved | 44 |
physical exercise | 44 |
protein response | 44 |
may provide | 44 |
porcine reproductive | 44 |
cytokine release | 44 |
performed using | 44 |
stem cell | 44 |
chicken embryo | 43 |
disease progression | 43 |
major role | 43 |
older adults | 43 |
inflammatory bowel | 43 |
respiratory disease | 43 |
pyramidal neurons | 43 |
new vaccine | 43 |
cholera toxin | 43 |
developing countries | 43 |
tlr agonists | 43 |
adaptive response | 43 |
two distinct | 43 |
gene transfer | 43 |
vaccine design | 43 |
influenza infection | 43 |
highly conserved | 43 |
better understanding | 43 |
distress syndrome | 42 |
mucosal vaccine | 42 |
gold nanoparticles | 42 |
autoimmune disease | 42 |
cytokine responses | 42 |
hcv core | 42 |
systemic lupus | 42 |
effector functions | 42 |
tnf production | 42 |
low levels | 42 |
cells may | 42 |
i ifns | 42 |
specific igg | 42 |
extracellular matrix | 42 |
vaccine adjuvant | 42 |
well known | 42 |
pregnant women | 42 |
two types | 42 |
phase ii | 42 |
hemorrhagic shock | 41 |
disease response | 41 |
science institute | 41 |
negative bacteria | 41 |
peritoneal macrophages | 41 |
allergic asthma | 41 |
wistar rats | 41 |
statistically significant | 41 |
olfactory bulb | 41 |
studies suggest | 41 |
national authorities | 41 |
humoral responses | 41 |
even though | 41 |
i response | 41 |
nmda receptor | 41 |
data show | 41 |
granule cells | 41 |
birth weight | 41 |
antibody production | 41 |
intranasal administration | 41 |
recent advances | 41 |
membrane protein | 40 |
crisis response | 40 |
environmental factors | 40 |
systemic immune | 40 |
tlr ligands | 40 |
pyramidal cells | 40 |
nanoparticle vaccines | 40 |
dynamic capabilities | 40 |
lupus erythematosus | 40 |
antiviral immune | 40 |
syndrome virus | 40 |
severe disease | 40 |
medical university | 40 |
inhibitory effect | 40 |
unfolded protein | 40 |
mucosal adjuvants | 40 |
blot analysis | 40 |
gnrh neurons | 40 |
wound healing | 39 |
cell biology | 39 |
responses induced | 39 |
vaccine formulation | 39 |
mucosal surfaces | 39 |
early life | 39 |
receptor expression | 39 |
fl uid | 39 |
intracellular pathogens | 39 |
helper cells | 39 |
influenza viruses | 39 |
inflammatory cells | 39 |
chronic stress | 39 |
hippocampal slices | 39 |
will discuss | 39 |
novel coronavirus | 39 |
global health | 39 |
world health | 39 |
osaka university | 39 |
antiviral responses | 38 |
cancer cells | 38 |
preclinical studies | 38 |
may represent | 38 |
fold change | 38 |
igg antibodies | 38 |
important roles | 38 |
cell activity | 38 |
adipose tissue | 38 |
oxide synthase | 38 |
cells showed | 38 |
oral vaccines | 38 |
mesenteric lymph | 38 |
new york | 38 |
endothelial cell | 38 |
large amounts | 38 |
data demonstrate | 38 |
avian influenza | 38 |
adjuvant activity | 38 |
may result | 37 |
ca i | 37 |
vaccination strategies | 37 |
normal mice | 37 |
cell wall | 37 |
cord blood | 37 |
myeloid cells | 37 |
rat brain | 37 |
chronic hepatitis | 37 |
low birth | 37 |
previous study | 37 |
may explain | 37 |
investigated whether | 37 |
mice infected | 37 |
fusion protein | 37 |
ubiquitin ligase | 37 |
disaster prevention | 37 |
several studies | 37 |
candidate genes | 37 |
controlled trial | 37 |
health organization | 37 |
attenuated vaccines | 37 |
cell repertoire | 37 |
psychological stress | 37 |
mice lacking | 36 |
iga antibodies | 36 |
inhibitory effects | 36 |
oral vaccine | 36 |
immune evasion | 36 |
disease severity | 36 |
alveolar macrophages | 36 |
ms patients | 36 |
dentate gyrus | 36 |
bowel disease | 36 |
response system | 36 |
survival rate | 36 |
histocompatibility complex | 36 |
cell migration | 36 |
remains unclear | 36 |
dengue virus | 36 |
rainbow trout | 36 |
differential expression | 36 |
cytokine secretion | 36 |
heart rate | 36 |
cytokine response | 36 |
viral variants | 36 |
local governments | 36 |
tissue injury | 36 |
iga responses | 36 |
zika virus | 36 |
time pcr | 36 |
sars coronavirus | 36 |
mhc i | 36 |
care unit | 36 |
response matching | 36 |
management system | 35 |
binding site | 35 |
ca region | 35 |
barrier function | 35 |
target cell | 35 |
interferon response | 35 |
vaccine candidate | 35 |
pandemic influenza | 35 |
upper respiratory | 35 |
rhesus macaques | 35 |
core protein | 35 |
tyrosine kinase | 35 |
crisis management | 35 |
following infection | 35 |
bacterial infection | 35 |
trauma patients | 35 |
disaster medicine | 35 |
complement activation | 35 |
inflammatory process | 35 |
high level | 35 |
tumor growth | 35 |
proinflammatory cytokine | 35 |
mass spectrometry | 35 |
expression patterns | 35 |
cells express | 35 |
lung function | 35 |
proliferative response | 35 |
facs analysis | 34 |
ctl escape | 34 |
risk communication | 34 |
disaster risk | 34 |
ifn production | 34 |
cells play | 34 |
reticulum stress | 34 |
dna immunization | 34 |
weight infants | 34 |
plasmodium falciparum | 34 |
wide variety | 34 |
protection motivation | 34 |
commonly used | 34 |
closely related | 34 |
memory cells | 34 |
time point | 34 |
infectious bronchitis | 34 |
functional genomics | 34 |
future studies | 34 |
research center | 34 |
will also | 34 |
i interferons | 34 |
human monocytes | 34 |
preterm neonates | 34 |
cardiac output | 34 |
coronavirus infection | 34 |
family members | 33 |
significant reduction | 33 |
kyoto univ | 33 |
th response | 33 |
promoter region | 33 |
mouse models | 33 |
cell mediated | 33 |
future research | 33 |
muscle cells | 33 |
membrane potential | 33 |
pivotal role | 33 |
specific cytotoxic | 33 |
model system | 33 |
lung tissue | 33 |
molecular mechanism | 33 |
monophosphoryl lipid | 33 |
expression level | 33 |
vaccine candidates | 33 |
signalling pathways | 33 |
intranasal immunization | 33 |
ill patients | 33 |
takes place | 33 |
significant role | 33 |
host innate | 33 |
well tolerated | 33 |
study showed | 33 |
tohoku university | 33 |
blood cells | 33 |
immunized mice | 33 |
widely used | 33 |
response induced | 33 |
bronchoalveolar lavage | 33 |
conjugate vaccine | 33 |
single cell | 33 |
subunit vaccine | 32 |
cells also | 32 |
real time | 32 |
examined whether | 32 |
tohoku univ | 32 |
rat hippocampal | 32 |
plasmacytoid dendritic | 32 |
adverse effects | 32 |
fish oil | 32 |
early stages | 32 |
expression profiling | 32 |
dna delivery | 32 |
respiratory infections | 32 |
dna sensing | 32 |
humoral response | 32 |
asthma patients | 32 |
genes associated | 32 |
new vaccines | 32 |
inflammatory processes | 32 |
significant decrease | 32 |
substantia nigra | 32 |
pathological changes | 32 |
emerging infectious | 32 |
sting pathway | 32 |
signal activation | 32 |
lymphoid tissue | 32 |
chitosan nanoparticles | 32 |
response may | 32 |
cell membranes | 32 |
cell signaling | 32 |
dna methylation | 32 |
also shown | 32 |
acute pancreatitis | 32 |
large numbers | 31 |
tumour necrosis | 31 |
pseudomonas aeruginosa | 31 |
naked dna | 31 |
may cause | 31 |
tlr agonist | 31 |
microarray analysis | 31 |
haemophilus influenzae | 31 |
cells via | 31 |
human disease | 31 |
expression changes | 31 |
studies showed | 31 |
growth cone | 31 |
ctl epitopes | 31 |
injection site | 31 |
therapeutic potential | 31 |
oral delivery | 31 |
studies indicate | 31 |
mhc molecules | 31 |
cationic liposomes | 31 |
western blotting | 31 |
viral antigens | 31 |
control animals | 31 |
expression profiles | 31 |
statistical analysis | 31 |
whole cell | 31 |
mg ml | 31 |
single dose | 31 |
associated lymphoid | 31 |
nasal vaccination | 31 |
free radicals | 31 |
ctl clones | 31 |
elevated levels | 31 |
naturally occurring | 31 |
significantly different | 31 |
equine influenza | 31 |
host factors | 30 |
recombinant protein | 30 |
outer membrane | 30 |
significantly enhanced | 30 |
binding proteins | 30 |
natural disasters | 30 |
protective effects | 30 |
candidate gene | 30 |
factor alpha | 30 |
tokyo metropolitan | 30 |
previously described | 30 |
largely unknown | 30 |
vitro studies | 30 |
may help | 30 |
short term | 30 |
human health | 30 |
node cells | 30 |
three different | 30 |
immune systems | 30 |
cellular response | 30 |
receptor signaling | 30 |
response syndrome | 30 |
nkt cell | 30 |
hiv vaccine | 30 |
brain regions | 30 |
immune mechanisms | 30 |
least two | 30 |
reverse vaccinology | 30 |
arachidonic acid | 30 |
host damage | 30 |
antibody levels | 30 |
lactic acid | 30 |
viral vector | 30 |
cytokines il | 30 |
bacterial translocation | 30 |
malaria vaccine | 30 |
low dose | 30 |
results suggested | 30 |
mouse brain | 30 |
coronavirus disease | 29 |
viral particles | 29 |
animal studies | 29 |
results indicated | 29 |
adaptive responses | 29 |
surface markers | 29 |
high frequency | 29 |
receptor activation | 29 |
total rna | 29 |
risk management | 29 |
authors declare | 29 |
treated animals | 29 |
analysis showed | 29 |
antigen receptor | 29 |
cell receptors | 29 |
oral administration | 29 |
nasal epithelium | 29 |
gram negative | 29 |
atopic dermatitis | 29 |
least one | 29 |
cells infected | 29 |
natural infection | 29 |
polyunsaturated fatty | 29 |
induced apoptosis | 29 |
cell recognition | 29 |
new approaches | 29 |
microbial pathogenesis | 29 |
risk factor | 29 |
tetanus toxoid | 29 |
life cycle | 29 |
blood vessels | 29 |
innate response | 29 |
adoptive transfer | 29 |
highly expressed | 29 |
vaccine responses | 29 |
systemic inflammation | 29 |
th cytokines | 29 |
murine model | 29 |
clinical signs | 29 |
allergic inflammation | 29 |
genetic variation | 29 |
oral vaccination | 29 |
thermal injury | 29 |
expressed genes | 28 |
biological activity | 28 |
viral clearance | 28 |
tgev infection | 28 |
basal ganglia | 28 |
oral immunization | 28 |
may occur | 28 |
pc cells | 28 |
nagoya university | 28 |
expression profi | 28 |
also able | 28 |
guinea pigs | 28 |
serum igg | 28 |
intranasal vaccination | 28 |
molecular biology | 28 |
digital technologies | 28 |
human clinical | 28 |
stress resilience | 28 |
vaccine vectors | 28 |
findings indicate | 28 |
antigenic peptides | 28 |
university hospital | 28 |
projection neurons | 28 |
group i | 28 |
intranasal delivery | 28 |
immunological memory | 28 |
sepsis syndrome | 28 |
healthy donors | 28 |
different cell | 28 |
transforming growth | 28 |
human cd | 28 |
type diabetes | 28 |
newborn infants | 28 |
riken brain | 28 |
muc ac | 28 |
human peripheral | 28 |
macrophage activation | 28 |
apache ii | 28 |
cell immunity | 28 |
specific iga | 28 |
lymphoid cells | 28 |
cell epitope | 28 |
studies show | 27 |
also showed | 27 |
epithelial barrier | 27 |
cytokine expression | 27 |
beneficial effects | 27 |
secretory iga | 27 |
west africa | 27 |
free radical | 27 |
government response | 27 |
response network | 27 |
ros production | 27 |
gene promoter | 27 |
mortality rate | 27 |
body temperature | 27 |
better understand | 27 |
sensory neurons | 27 |
auditory cortex | 27 |
vaccine safety | 27 |
significantly elevated | 27 |
studies revealed | 27 |
small intestine | 27 |
neural network | 27 |
modified vaccinia | 27 |
response plan | 27 |
gamma delta | 27 |
also increased | 27 |
inflammatory disease | 27 |
mortality rates | 27 |
early stage | 27 |
dna sensor | 27 |
motor neurons | 27 |
vascular permeability | 27 |
common cold | 27 |
high degree | 27 |
identifi ed | 27 |
passive protection | 27 |
plasma concentrations | 27 |
helper cell | 27 |
high dose | 27 |
blood donors | 27 |
neural activity | 27 |
proliferative responses | 27 |
brain function | 27 |
different stages | 26 |
rat model | 26 |
reperfusion injury | 26 |
genetic factors | 26 |
mean age | 26 |
hippocampal ca | 26 |
immune complex | 26 |
single cells | 26 |
asthma exacerbations | 26 |
lymphocyte responses | 26 |
clinical course | 26 |
new therapeutic | 26 |
cell rna | 26 |
bronchial epithelial | 26 |
provide evidence | 26 |
receptive field | 26 |
crisis responses | 26 |
inflammatory effects | 26 |
mucosal iga | 26 |
deer mice | 26 |
first line | 26 |
cause disease | 26 |
antigen specific | 26 |
binding sites | 26 |
type immune | 26 |
one hand | 26 |
neurite outgrowth | 26 |
weight loss | 26 |
many different | 26 |
complement system | 26 |
may reflect | 26 |
phase proteins | 26 |
transmissible gastroenteritis | 26 |
induced arthritis | 26 |
primary infection | 26 |
promoter activity | 26 |
recombinant human | 26 |
currently available | 26 |
expression pattern | 26 |
mammalian cells | 26 |
newcastle disease | 26 |
stimulatory molecules | 26 |
insulin resistance | 26 |
specific cellular | 26 |
antimicrobial peptides | 26 |
linked poly | 26 |
electron microscopy | 26 |
vaccine antigen | 26 |
information processing | 26 |
analysis using | 25 |
soluble tnf | 25 |
brain injury | 25 |
blood lymphocytes | 25 |
ctl activity | 25 |
viral protein | 25 |
serine protease | 25 |
cancer patients | 25 |
new insights | 25 |
cell cultures | 25 |
surface receptors | 25 |
infected cell | 25 |
dose dependent | 25 |
cell growth | 25 |
chain reaction | 25 |
human papillomavirus | 25 |
produce il | 25 |
pupil diameter | 25 |
particle size | 25 |
cancer cell | 25 |
young children | 25 |
essential role | 25 |
novel therapeutic | 25 |
mouse strains | 25 |
life science | 25 |
healthy adults | 25 |
term potentiation | 25 |
wt mice | 25 |
human diseases | 25 |
systems vaccinology | 25 |
profi ling | 25 |
data sets | 25 |
mice treated | 25 |
may affect | 25 |
light reflex | 25 |
ibv infection | 25 |
langerhans cells | 25 |
induced cytokine | 25 |
i mhc | 25 |
sendai virus | 25 |
bronchitis virus | 25 |
south korea | 25 |
first days | 25 |
gabaergic neurons | 25 |
vitro stimulation | 25 |
cytokine profile | 25 |
tlr expression | 25 |
candidate vaccines | 25 |
cell immune | 25 |
phagocytic cells | 25 |
map kinase | 25 |
lps challenge | 25 |
dopaminergic neurons | 25 |
cancer immunotherapy | 25 |
human immune | 25 |
negative sepsis | 25 |
cell level | 25 |
results obtained | 25 |
high concentrations | 25 |
fever virus | 25 |
emerging pathogens | 25 |
local government | 25 |
ml kg | 25 |
may induce | 24 |
blood cell | 24 |
therapeutic agents | 24 |
therapeutic targets | 24 |
adaptor protein | 24 |
well established | 24 |
lymphoid organs | 24 |
cell analysis | 24 |
induced immune | 24 |
expressing cells | 24 |
polymerase chain | 24 |
foreign antigens | 24 |
arterial pressure | 24 |
receptor gene | 24 |
recently reported | 24 |
disease control | 24 |
vaccine strategies | 24 |
core expression | 24 |
may influence | 24 |
purkinje cell | 24 |
shock proteins | 24 |
secreted protein | 24 |
patients undergoing | 24 |
early phase | 24 |
transgenic mouse | 24 |
united kingdom | 24 |
immune surveillance | 24 |
genomic dna | 24 |
evidence suggests | 24 |
apoptotic cell | 24 |
neuropathic pain | 24 |
ganglion cells | 24 |
phagocytic activity | 24 |
responses following | 24 |
virus ankara | 24 |
associated protein | 24 |
another study | 24 |
host interactions | 24 |
also reported | 24 |
cd mab | 24 |
response genes | 24 |
rabies virus | 24 |
block copolymers | 24 |
core gene | 24 |
vaccine immunogenicity | 24 |
investigate whether | 24 |
hydrogen peroxide | 24 |
negatively charged | 24 |
infection may | 24 |
immune functions | 24 |
transcriptional response | 24 |
mucosal adjuvant | 24 |
nanoparticle vaccine | 24 |
patients suffering | 24 |
venous blood | 24 |
information sharing | 24 |
igg responses | 24 |
human cells | 24 |
antigen expression | 24 |
within hours | 24 |
health emergencies | 24 |
studies demonstrated | 24 |
whole genome | 24 |
th cell | 24 |
neuronal cell | 24 |
tnf receptor | 24 |
red blood | 24 |
immune protection | 24 |
inactivated influenza | 24 |
tg mice | 24 |
human rotavirus | 24 |
gastrointestinal tract | 24 |
dorsal root | 24 |
brain development | 24 |
locomotor activity | 24 |
small number | 24 |
hcv infection | 24 |
related genes | 24 |
still unclear | 24 |
secreting cells | 24 |
response framework | 24 |
significantly inhibited | 24 |
inflammatory conditions | 24 |
two major | 24 |
i will | 24 |
like particle | 24 |
cov infection | 24 |
big data | 24 |
influencing disaster | 23 |
surface area | 23 |
based nanoparticles | 23 |
randomized controlled | 23 |
nmda receptors | 23 |
treated rats | 23 |
will need | 23 |
respiratory failure | 23 |
white blood | 23 |
bacillus anthracis | 23 |
actin cytoskeleton | 23 |
response time | 23 |
dendritic spines | 23 |
cystic fibrosis | 23 |
tlr signaling | 23 |
effective vaccines | 23 |
marginal zone | 23 |
much less | 23 |
transgene expression | 23 |
result suggests | 23 |
surface proteins | 23 |
defense mechanisms | 23 |
medical research | 23 |
cell memory | 23 |
lessons learned | 23 |
mice compared | 23 |
host defence | 23 |
effective response | 23 |
play important | 23 |
persistent infection | 23 |
vaccine induces | 23 |
neural activities | 23 |
positive correlation | 23 |
fi rst | 23 |
showed significant | 23 |
vitro experiments | 23 |
lps stimulation | 23 |
important factor | 23 |
translation initiation | 23 |
adult mice | 23 |
recombinant proteins | 23 |
male wistar | 23 |
severe asthma | 23 |
expression profile | 23 |
barr virus | 23 |
give rise | 23 |
inflammatory reactions | 23 |
th immune | 23 |
ca pyramidal | 23 |
effective disaster | 23 |
virus core | 23 |
cd cell | 23 |
limiting dilution | 23 |
organ injury | 23 |
pupillary light | 23 |
behavior change | 23 |
activation markers | 23 |
million people | 23 |
acute infection | 23 |
medical center | 23 |
vaccines may | 23 |
nonhuman primates | 23 |
confer protection | 23 |
patients infected | 23 |
gene gun | 23 |
i antigen | 23 |
cell hybridomas | 23 |
beneficial effect | 23 |
glutamate receptor | 23 |
recombinant lactobacillus | 22 |
tnf receptors | 22 |
highly pathogenic | 22 |
transcriptional regulation | 22 |
nerve injury | 22 |
shock protein | 22 |
gene product | 22 |
underlying mechanisms | 22 |
specific antigen | 22 |
restricted cytotoxic | 22 |
control groups | 22 |
fully understood | 22 |
preliminary data | 22 |
igg antibody | 22 |
marked increase | 22 |
fear memory | 22 |
diabetes mellitus | 22 |
lipid peroxidation | 22 |
kinase inhibitors | 22 |
inducible nitric | 22 |
defi ned | 22 |
pathogen recognition | 22 |
post infection | 22 |
inflammatory activity | 22 |
health systems | 22 |
levels increased | 22 |
broadly neutralizing | 22 |
specific response | 22 |
molecular basis | 22 |
wide association | 22 |
significant correlation | 22 |
creative commons | 22 |
dorsal horn | 22 |
nasal delivery | 22 |
days later | 22 |
oxygen delivery | 22 |
recombinant vaccinia | 22 |
cells respond | 22 |
using anti | 22 |
dependent signal | 22 |
lymphocyte proliferation | 22 |
cell infiltration | 22 |
hbv infection | 22 |
patients treated | 22 |
structural proteins | 22 |
measles virus | 22 |
signaling molecules | 22 |
gel electrophoresis | 22 |
primary human | 22 |
staphylococcus aureus | 22 |
cecal ligation | 22 |
tlr ligand | 22 |
dominant negative | 22 |
social media | 22 |
gene transcription | 22 |
gnotobiotic pigs | 22 |
mucosal vaccination | 22 |
induced activation | 22 |
killer cells | 22 |
similar results | 22 |
keio univ | 22 |
binding domain | 22 |
kg day | 22 |
riken bsi | 22 |
cell damage | 22 |
promising results | 22 |
peptide binding | 22 |
term neonates | 22 |
gene encoding | 22 |
colony stimulating | 22 |
cells stimulated | 22 |
also used | 22 |
protein level | 22 |
highly effective | 22 |
confocal microscopy | 22 |
clinical study | 22 |
neuronal differentiation | 22 |
nasal cavity | 22 |
expression analysis | 22 |
monocytes macrophages | 22 |
federal government | 22 |
significant changes | 22 |
cell tolerance | 22 |
informal settlements | 22 |
immune escape | 22 |
biology approach | 21 |
cell transplantation | 21 |
passive immunity | 21 |
infectious agent | 21 |
influenzae type | 21 |
therapeutic vaccines | 21 |
protects mice | 21 |
specific cell | 21 |
specific memory | 21 |
magnetic resonance | 21 |
chronic diseases | 21 |
simulation results | 21 |
neurotrophic factor | 21 |
increased mortality | 21 |
virus vaccines | 21 |
experimental models | 21 |
mhc ii | 21 |
nuclear power | 21 |
organ damage | 21 |
vascular resistance | 21 |
vaccine administration | 21 |
novel vaccine | 21 |
genetic variants | 21 |
surface antigens | 21 |
responses may | 21 |
also important | 21 |
target genes | 21 |
macrophage colony | 21 |
different mechanisms | 21 |
dna virus | 21 |
human airway | 21 |
ebola response | 21 |
cell layer | 21 |
local immune | 21 |
broad spectrum | 21 |
candidate vaccine | 21 |
secreted proteins | 21 |
genes encoding | 21 |
adult rats | 21 |
delivery vehicles | 21 |
mers outbreak | 21 |
lymphocytic choriomeningitis | 21 |
health system | 21 |
surface molecules | 21 |
dna prime | 21 |
increased production | 21 |
ebola outbreak | 21 |
receptor agonists | 21 |
major cause | 21 |
disseminated intravascular | 21 |
many studies | 21 |
specific immunity | 21 |
gut microbiota | 21 |
female mice | 21 |
acute stress | 21 |
systemic immunity | 21 |
new technologies | 21 |
antiviral immunity | 21 |
mucociliary clearance | 21 |
marrow derived | 21 |
neurodegenerative diseases | 21 |
renal failure | 21 |
nuclear translocation | 21 |
goblet cell | 21 |
vaccine vector | 21 |
clinical outcome | 21 |
therapeutic approaches | 21 |
inflammatory mediator | 21 |
motor learning | 21 |
various types | 21 |
inflammatory cell | 21 |
effective vaccine | 21 |
streptococcus pneumoniae | 21 |
surround suppression | 21 |
mediated responses | 21 |
guinea pig | 21 |
novel actors | 21 |
clinical practice | 21 |
tuberculosis infection | 21 |
ii molecules | 21 |
sd model | 21 |
recent work | 21 |
will provide | 21 |
vivo studies | 21 |
transfection efficiency | 21 |
vaccine response | 21 |
recent evidence | 21 |
innate leukocytes | 21 |
working memory | 21 |
genetically engineered | 20 |
primary motor | 20 |
shed light | 20 |
highly purified | 20 |
less likely | 20 |
fluorescent protein | 20 |
th cytokine | 20 |
sequence analysis | 20 |
inflammatory reaction | 20 |
will help | 20 |
cd cytotoxic | 20 |
serum antibodies | 20 |
relatively high | 20 |
high titers | 20 |
modifying therapies | 20 |
regulatory factor | 20 |
cell maturation | 20 |
genetic background | 20 |
well understood | 20 |
reservoir hosts | 20 |
single nucleotide | 20 |
public crisis | 20 |
systemic vascular | 20 |
male rats | 20 |
mediated dna | 20 |
allowed us | 20 |
serum il | 20 |
glycolic acid | 20 |
membrane proteins | 20 |
first step | 20 |
recently identified | 20 |
synaptic vesicles | 20 |
measured using | 20 |
cell functions | 20 |
commercially available | 20 |
receptor antagonists | 20 |
real scenarios | 20 |
heavy chain | 20 |
cells following | 20 |
experimental animals | 20 |
brain activity | 20 |
necrotizing enterocolitis | 20 |
antigen uptake | 20 |
several different | 20 |
including il | 20 |
respiratory viruses | 20 |
take place | 20 |
another important | 20 |
mm hg | 20 |
cell help | 20 |
immunomodulatory activity | 20 |
human volunteers | 20 |
listeria monocytogenes | 20 |
high risk | 20 |
transmitter release | 20 |
unclear whether | 20 |
sle patients | 20 |
mouth disease | 20 |
cpg motifs | 20 |
immune suppression | 20 |
data collection | 20 |
rna interference | 20 |
large scale | 20 |
arterial blood | 20 |
invading pathogens | 20 |
immune tolerance | 20 |
danger signals | 20 |
culture medium | 20 |
growth hormone | 20 |
fos expression | 20 |
plasma cell | 20 |
cell survival | 20 |
potential therapeutic | 20 |
mucosal tissues | 20 |
airway remodeling | 20 |
australian government | 20 |
medical science | 20 |
local disaster | 20 |
cell subset | 20 |
cell numbers | 20 |
innate responses | 20 |
recombinant vaccine | 20 |
lactobacillus vaccine | 20 |
cytokine il | 20 |
choriomeningitis virus | 20 |
civil society | 20 |
interferon gamma | 20 |
induced cell | 20 |
i expression | 20 |
viral pathogens | 20 |
mechanism underlying | 20 |
cell specific | 20 |
level evidence | 20 |
uric acid | 20 |
vaccine encoding | 20 |
gene segments | 20 |
two main | 20 |
receptor agonist | 20 |
nasal mucosa | 19 |
neutrophil elastase | 19 |
neuronal death | 19 |
study aimed | 19 |
gene polymorphisms | 19 |
food intake | 19 |
inflammatory properties | 19 |
synaptic inputs | 19 |
biologically active | 19 |
antibodies directed | 19 |
safety profile | 19 |
medical sciences | 19 |
reverse genetics | 19 |
cd antibodies | 19 |
derived dendritic | 19 |
protein production | 19 |
constitutively expressed | 19 |
adjuvant effect | 19 |
antiviral mabs | 19 |
gene polymorphism | 19 |
ndv infection | 19 |
different time | 19 |
preliminary results | 19 |
chronic disease | 19 |
family member | 19 |
three weeks | 19 |
evidence indicates | 19 |
health threat | 19 |
lavage fluid | 19 |
metropolitan institute | 19 |
airway hyper | 19 |
also induced | 19 |
cytotoxic activity | 19 |
tyrosine phosphorylation | 19 |
cd ro | 19 |
digital transformation | 19 |
electrical stimulation | 19 |
years ago | 19 |
derived macrophages | 19 |
freshly isolated | 19 |
increased susceptibility | 19 |
mean arterial | 19 |
term memory | 19 |
patients without | 19 |
clinical symptoms | 19 |
relatively low | 19 |
cell bodies | 19 |
results provide | 19 |
damage response | 19 |
possible role | 19 |
cells producing | 19 |
public sentiments | 19 |
neuronal migration | 19 |
i restricted | 19 |
tumor cell | 19 |
human skin | 19 |
breast cancer | 19 |
multiple trauma | 19 |
heart disease | 19 |
marrow cells | 19 |
highly immunogenic | 19 |
nagoya univ | 19 |
adjuvant system | 19 |
activating factor | 19 |
es cells | 19 |
axon terminals | 19 |
measles vaccine | 19 |
infected animals | 19 |
cell proliferative | 19 |
vaccines based | 19 |
disease caused | 19 |
northern blot | 19 |
intracellular calcium | 19 |
serum samples | 19 |
st century | 19 |
vaccine based | 19 |
arm model | 19 |
regulatory cells | 19 |
enhanced immune | 19 |
also present | 19 |
studies will | 19 |
determined using | 19 |
quality control | 19 |
intravascular coagulation | 19 |
bacterial sepsis | 19 |
lower respiratory | 19 |
immune recognition | 19 |
neurons showed | 19 |
transduction pathways | 19 |
mediated gene | 19 |
cardiovascular disease | 19 |
burn injury | 19 |
proteins involved | 19 |
antigen recognition | 19 |
increase rate | 19 |
i antigens | 19 |
human subjects | 19 |
disease outbreaks | 19 |
also involved | 19 |
poly i | 19 |
spike protein | 19 |
immune genes | 19 |
severe covid | 19 |
blood transfusion | 19 |
mice developed | 18 |
natural disaster | 18 |
lamina propria | 18 |
based adjuvants | 18 |
also associated | 18 |
human neutrophils | 18 |
cells compared | 18 |
community structure | 18 |
acute lung | 18 |
mice expressing | 18 |
cellular stress | 18 |
vaccine containing | 18 |
acute inflammatory | 18 |
specific antigens | 18 |
ischemia reperfusion | 18 |
adult male | 18 |
gives rise | 18 |
protein folding | 18 |
helicobacter pylori | 18 |
glucocorticoid receptor | 18 |
broad range | 18 |
protective antigen | 18 |
tlr activation | 18 |
i clinical | 18 |
lps injection | 18 |
innate antiviral | 18 |
study also | 18 |
two weeks | 18 |
lps induced | 18 |
trout nalt | 18 |
mediated signaling | 18 |
one group | 18 |
control variables | 18 |
tlr stimulation | 18 |
retinoic acid | 18 |
chronic obstructive | 18 |
immune regulation | 18 |
clonal expansion | 18 |
will require | 18 |
emergency preparedness | 18 |
immune status | 18 |
genetic polymorphisms | 18 |
vaccine production | 18 |
microorganism interaction | 18 |
disease activity | 18 |
one study | 18 |
three times | 18 |
study using | 18 |
bacterial cell | 18 |
rna virus | 18 |
cells using | 18 |
sex differences | 18 |
pulmonary disease | 18 |
without affecting | 18 |
serum antibody | 18 |
response will | 18 |
least three | 18 |
another example | 18 |
salmonella typhimurium | 18 |
killer cell | 18 |
novel adjuvants | 18 |
university medical | 18 |
homeland security | 18 |
converting enzyme | 18 |
mucosal delivery | 18 |
antigen receptors | 18 |
plga nanoparticles | 18 |
well characterized | 18 |
surface protein | 18 |
lymphokine production | 18 |
enhance immune | 18 |
virus dna | 18 |
cell lysis | 18 |
virus particles | 18 |
body surface | 18 |
clinical presentation | 18 |
peptide vaccine | 18 |
cytokine profiles | 18 |
low doses | 18 |
three groups | 18 |
major surgery | 18 |
may act | 18 |
may increase | 18 |
germinal center | 18 |
virulence factors | 18 |
action potentials | 18 |
lower levels | 18 |
white matter | 18 |
association studies | 18 |
type virus | 18 |
preclinical models | 18 |
emergency nurses | 18 |
inducible gene | 18 |
mucosal immunization | 18 |
negative regulator | 18 |
chemokine receptor | 18 |
escape mutations | 18 |
analyzed using | 18 |
placebo group | 18 |
life sciences | 18 |
abdominal sepsis | 18 |
escape viral | 18 |
human brain | 18 |
inflammasome activation | 18 |
protective role | 18 |
kupffer cells | 18 |
immersion vaccination | 18 |
effective immune | 18 |
virus challenge | 18 |
aids vaccine | 18 |
strong immune | 18 |
digital technology | 18 |
costimulatory molecules | 18 |
incubation period | 18 |
recently shown | 18 |
silica nanoparticles | 18 |
blood levels | 18 |
years old | 18 |
mice exhibited | 18 |
limited number | 18 |
protein kinases | 18 |
pulmonary artery | 18 |
enzymatic activity | 18 |
pharmaceutical sciences | 18 |
therapeutic approach | 18 |
per se | 18 |
also reduced | 18 |
positively charged | 18 |
response elicited | 18 |
induced il | 18 |
plasma il | 18 |
ebola infection | 18 |
fever vaccine | 18 |
decision making | 18 |
brain research | 18 |
human vaccines | 18 |
scientific research | 18 |
activated receptor | 18 |
see ch | 18 |
visual information | 18 |
identifi cation | 18 |
clinical disease | 18 |
cancer vaccines | 17 |
mrna level | 17 |
vaccine platform | 17 |
surface charge | 17 |
th type | 17 |
vesicular stomatitis | 17 |
pupil size | 17 |
mechanical ventilation | 17 |
biological activities | 17 |
japan science | 17 |
jurkat cells | 17 |
sentiment system | 17 |
human blood | 17 |
one example | 17 |
experimental model | 17 |
light stimulus | 17 |
therapeutic efficacy | 17 |
tissue factor | 17 |
also significantly | 17 |
induced colitis | 17 |
activated cd | 17 |
hla alleles | 17 |
increased significantly | 17 |
among different | 17 |
hemorrhagic fever | 17 |
critical illness | 17 |
may involve | 17 |
local inflammatory | 17 |
circumsporozoite protein | 17 |
different levels | 17 |
proteolytic activity | 17 |
protein boost | 17 |
receptor binding | 17 |
study examined | 17 |
presynaptic terminals | 17 |
ii score | 17 |
intramuscular injection | 17 |
restricted ctl | 17 |
cells derived | 17 |
regression analysis | 17 |
protect mice | 17 |
embryonic development | 17 |
human genome | 17 |
climate change | 17 |
air pollution | 17 |
fusion proteins | 17 |
primary immune | 17 |
vaccine approaches | 17 |
disease models | 17 |
granule cell | 17 |
rational design | 17 |
natural hazards | 17 |
human studies | 17 |
profi le | 17 |
vgamma vdelta | 17 |
cytoplasmic domain | 17 |
intracellular dna | 17 |
recent progress | 17 |
study investigated | 17 |
morphological changes | 17 |
elderly population | 17 |
cell lysates | 17 |
fmri study | 17 |
late phase | 17 |
labeled cells | 17 |
antiviral activity | 17 |
cell viability | 17 |
normal human | 17 |
lung inflammation | 17 |
deleterious effects | 17 |
host immunity | 17 |
umbilical cord | 17 |
expression system | 17 |
type iii | 17 |
nude mice | 17 |
dna complexes | 17 |
cell count | 17 |
scid mice | 17 |
interface habits | 17 |
specific ige | 17 |
shed blood | 17 |
adjuvanted vaccines | 17 |
specific ifn | 17 |
extensively studied | 17 |
nucleocapsid protein | 17 |
vice versa | 17 |
nasal secretions | 17 |
potential vaccine | 17 |
pathological conditions | 17 |
therapeutic vaccine | 17 |
culture system | 17 |
reporter gene | 17 |
immunological synapse | 17 |
expression data | 17 |
infl ammation | 17 |
septic response | 17 |
joint inflammation | 17 |
like protease | 17 |
activated macrophages | 17 |
motor cortex | 17 |
physiological sciences | 17 |
central government | 17 |
study revealed | 17 |
ec ii | 17 |
regulated genes | 17 |
chain fatty | 17 |
respiratory epithelial | 17 |
respiratory pathogens | 17 |
physiological role | 17 |
cd clones | 17 |
lymphocyte activation | 17 |
critical care | 17 |
rem sleep | 17 |
influencing infectious | 17 |
tokyo medical | 17 |
mice deficient | 17 |
oxygen radicals | 17 |
regulatory role | 17 |
glutamate receptors | 17 |
transfected cells | 17 |
cell stimulation | 17 |
weeks post | 17 |
potent anti | 17 |
immune control | 17 |
vaccine research | 17 |
gene regulation | 17 |
nasal epithelial | 17 |
digital media | 17 |
mpxv infection | 17 |
data obtained | 17 |
also detected | 17 |
acid sequence | 17 |
pam csk | 16 |
patients compared | 16 |
inflammatory stress | 16 |
causative agent | 16 |
second messenger | 16 |
ulcerative colitis | 16 |
cells expressed | 16 |
protein vaccine | 16 |
safety concerns | 16 |
income countries | 16 |
analysis demonstrated | 16 |
pathogen interactions | 16 |
cell technologies | 16 |
therapeutic strategies | 16 |
high mortality | 16 |
intracellular pathogen | 16 |
clinical features | 16 |
national institutes | 16 |
cell number | 16 |
surgical trauma | 16 |
factor receptor | 16 |
mucosal surface | 16 |
sensitive dye | 16 |
initial response | 16 |
adult rat | 16 |
serum cytokine | 16 |
reserve capacity | 16 |
partial protection | 16 |
programmed cell | 16 |
amplifying rna | 16 |
generally accepted | 16 |
experimental infection | 16 |
applied biosystems | 16 |
peritoneal cavity | 16 |
acquired pneumonia | 16 |
target antigen | 16 |
like il | 16 |
infrared spectroscopy | 16 |
thyroid hormone | 16 |
superoxide dismutase | 16 |
ms disease | 16 |
core aa | 16 |
macrophage inflammatory | 16 |
wildtype mice | 16 |
important implications | 16 |
strongly suggest | 16 |
induced tnf | 16 |
recombinant dna | 16 |
binding lectin | 16 |
viral epitopes | 16 |
axon guidance | 16 |
oxygen saturation | 16 |
eye movement | 16 |
tight junctions | 16 |
liver injury | 16 |
nod mice | 16 |
pulmonary fibrosis | 16 |
diseases like | 16 |
infectious hematopoietic | 16 |
still unknown | 16 |
cd positive | 16 |
nadph oxidase | 16 |
antibody titer | 16 |
cytokine genes | 16 |
habit formation | 16 |
also identified | 16 |
expressing cd | 16 |
next generation | 16 |
recently developed | 16 |
elevated expression | 16 |
chronic infection | 16 |
intracellular ca | 16 |
receptive fields | 16 |
studies demonstrate | 16 |
immunomodulatory properties | 16 |
asthma control | 16 |
data analysis | 16 |
cortical areas | 16 |
neural progenitor | 16 |
group ii | 16 |
da neurons | 16 |
health behaviors | 16 |
also occur | 16 |
niigata university | 16 |
cell priming | 16 |
precursor cells | 16 |
obstructive pulmonary | 16 |
legionella pneumophila | 16 |
kg i | 16 |
polymeric nanoparticles | 16 |
intraperitoneal injection | 16 |
stimulated genes | 16 |
plasminogen activator | 16 |
study suggests | 16 |
stomatitis virus | 16 |
treated group | 16 |
flow cytometric | 16 |
existing studies | 16 |
rat hippocampus | 16 |
analysis indicated | 16 |
one week | 16 |
information regarding | 16 |
targeted delivery | 16 |
eye movements | 16 |
glutamic acid | 16 |
cellular uptake | 16 |
high doses | 16 |
steady state | 16 |
capsid protein | 16 |
allergic airway | 16 |
system may | 16 |
life sci | 16 |
plasma endotoxin | 16 |
dependent innate | 16 |
functional significance | 16 |
human monoclonal | 16 |
statistical significance | 16 |
inflammatory effect | 16 |
hematopoietic necrosis | 16 |
boost regimen | 16 |
human leukocyte | 16 |
risk assessment | 16 |
well defined | 16 |
biological effects | 16 |
mice using | 16 |
pulmonary hypertension | 16 |
two days | 16 |
individual differences | 16 |
regulatory mechanisms | 16 |
lethal challenge | 16 |
higher expression | 16 |
sin nombre | 16 |
effective treatment | 16 |
responses elicited | 16 |
il il | 16 |
fine specificity | 16 |
network analysis | 16 |
per day | 16 |
intracellular bacteria | 16 |
antigen discovery | 16 |
specific manner | 16 |
might also | 16 |
nuclear knowledge | 16 |
among others | 16 |
cells isolated | 16 |
whole body | 16 |
th day | 16 |
attenuated vaccine | 16 |
provide new | 16 |
intestinal epithelial | 16 |
different aspects | 15 |
pcr analysis | 15 |
response following | 15 |
cognitive function | 15 |
neural development | 15 |
functional roles | 15 |
several types | 15 |
will lead | 15 |
iav infection | 15 |
sting function | 15 |
insulin sensitivity | 15 |
terrorist attack | 15 |
cell clone | 15 |
new approach | 15 |
markedly reduced | 15 |
long time | 15 |
modified live | 15 |
regulatory proteins | 15 |
bacterial lipopolysaccharide | 15 |
will allow | 15 |
serum albumin | 15 |
cells specific | 15 |
will focus | 15 |
kyushu institute | 15 |
bacterial growth | 15 |
treated patients | 15 |
virus strains | 15 |
induced production | 15 |
terminal region | 15 |
health authorities | 15 |
total body | 15 |
presenting cell | 15 |
labile toxin | 15 |
tightly regulated | 15 |
current response | 15 |
colon cancer | 15 |
attenuated live | 15 |
observations suggest | 15 |
negative effects | 15 |
firing rate | 15 |
following trauma | 15 |
data provide | 15 |
markedly increased | 15 |
also affect | 15 |
iron oxide | 15 |
inflammatory genes | 15 |
patients received | 15 |
significant improvement | 15 |
inflammatory disorders | 15 |
brain sci | 15 |
virulent rv | 15 |
low molecular | 15 |
feedback loop | 15 |
vast majority | 15 |
disease prevention | 15 |
lesser extent | 15 |
vascular endothelial | 15 |
negative feedback | 15 |
barrier integrity | 15 |
synthetic peptide | 15 |
phase response | 15 |
small interfering | 15 |
west african | 15 |
cell interactions | 15 |
also tested | 15 |
intestinal inflammation | 15 |
therapeutic intervention | 15 |
tnf levels | 15 |
case study | 15 |
active immunity | 15 |
clinical efficacy | 15 |
transcriptional activity | 15 |
different strategies | 15 |
host antiviral | 15 |
early response | 15 |
within days | 15 |
wellness response | 15 |
cord injury | 15 |
response activities | 15 |
conventional vaccines | 15 |
breast milk | 15 |
mesoporous silica | 15 |
comparative analysis | 15 |
bacterial pathogens | 15 |
enhanced immunogenicity | 15 |
molecular signatures | 15 |
quantitative analysis | 15 |
toxoplasma gondii | 15 |
past decade | 15 |
extremely low | 15 |
hpa axis | 15 |
two hours | 15 |
frontal cortex | 15 |
mitochondrial dna | 15 |
perceived vulnerability | 15 |
rotavirus infection | 15 |
calcium influx | 15 |
specific responses | 15 |
proinfl ammatory | 15 |
effector function | 15 |
hematopoietic stem | 15 |
different pathogens | 15 |
one year | 15 |
nasal vaccine | 15 |
significantly correlated | 15 |
also play | 15 |
developed countries | 15 |
specific monoclonal | 15 |
cytokine receptors | 15 |
potent immune | 15 |
coupled receptors | 15 |
plasma samples | 15 |
platelet aggregation | 15 |
response team | 15 |
present data | 15 |
immune defense | 15 |
care workers | 15 |
septic complications | 15 |
suppressor cells | 15 |
newly emerging | 15 |
synapse formation | 15 |
domain knowledge | 15 |
receptor complex | 15 |
negative selection | 15 |
three major | 15 |
oleic acid | 15 |
hepatitis virus | 15 |
pediatric sepsis | 15 |
disease pathogenesis | 15 |
financial support | 15 |
live vaccines | 15 |
increased cd | 15 |
related diseases | 15 |
spatial frequency | 15 |
human nasal | 15 |
recently demonstrated | 15 |
culture supernatants | 15 |
present results | 15 |
particularly important | 15 |
four different | 15 |
infected host | 15 |
medical care | 15 |
cerebellar cortex | 15 |
gold nanoparticle | 15 |
clinical use | 15 |
health services | 15 |
informed consent | 15 |
mice revealed | 15 |
visual stimuli | 15 |
vaccine components | 15 |
vaccine carrier | 15 |
genetic susceptibility | 15 |
patients receiving | 15 |
mpo activity | 15 |
pulmonary syndrome | 15 |
neuronal damage | 15 |
mucosal sites | 15 |
direct interaction | 15 |
respiratory infection | 15 |
treatment group | 15 |
cerebral malaria | 15 |
adjuvanted vaccine | 15 |
previously demonstrated | 15 |
many years | 15 |
adult respiratory | 15 |
generation model | 15 |
human lung | 15 |
interacting protein | 15 |
control cells | 15 |
sepsis may | 15 |
potential role | 15 |
three types | 15 |
tract infections | 15 |
linolenic acid | 15 |
ifn therapy | 15 |
type hypersensitivity | 15 |
city university | 15 |
bordetella pertussis | 15 |
mg dl | 15 |
law enforcement | 15 |
tyrosine kinases | 15 |
quantitative rt | 15 |
i ii | 15 |
optical imaging | 15 |
protein antigen | 15 |
fold higher | 15 |
rotavirus vaccine | 14 |
ii clinical | 14 |
viral genes | 14 |
functional role | 14 |
knowledge embedding | 14 |
identify novel | 14 |
medial prefrontal | 14 |
granulocyte colony | 14 |
combination therapy | 14 |
chronic viral | 14 |
gray matter | 14 |
also examined | 14 |
baseline values | 14 |
clinical evaluation | 14 |
negative bacterial | 14 |
soluble form | 14 |
expression studies | 14 |
cohesive subgroups | 14 |
modern vaccines | 14 |
also expressed | 14 |
high expression | 14 |
low concentrations | 14 |
like structures | 14 |
rna sequencing | 14 |
deficient cells | 14 |
prominent role | 14 |
envelope protein | 14 |
primary response | 14 |
significantly associated | 14 |
well described | 14 |
vaccines currently | 14 |
beta i | 14 |
fluorescence microscopy | 14 |
hokkaido university | 14 |
protective antibody | 14 |
examined using | 14 |
terrorist attacks | 14 |
inflammatory agents | 14 |
bovine serum | 14 |
clinical manifestations | 14 |
two studies | 14 |
suppressive effect | 14 |
viral dna | 14 |
crp levels | 14 |
critical period | 14 |
recent findings | 14 |
significantly larger | 14 |
glutamate transporters | 14 |
coli heat | 14 |
kir dl | 14 |
may become | 14 |
nucleotide sequence | 14 |
blood stream | 14 |
diseases including | 14 |
common cause | 14 |
dependent protein | 14 |
aluminum hydroxide | 14 |
studied using | 14 |
initiation factor | 14 |
superoxide production | 14 |
per group | 14 |
transcriptional activation | 14 |
hematopoietic cells | 14 |
likely due | 14 |
sciatic nerve | 14 |
insulin insensitivity | 14 |
cell lineage | 14 |
also provide | 14 |
significantly improved | 14 |
ifn treatment | 14 |
prime boost | 14 |
positive neurons | 14 |
factors involved | 14 |
signifi cant | 14 |
primary visual | 14 |
inflammatory markers | 14 |
bacterial toxins | 14 |
adherent cells | 14 |
hla molecules | 14 |
lung epithelial | 14 |
group showed | 14 |
social isolation | 14 |
kinase activity | 14 |
developmental stages | 14 |
cmv infection | 14 |
dna binding | 14 |
vaccination strategy | 14 |
assay using | 14 |
increased il | 14 |
patients may | 14 |
higher antibody | 14 |
mitochondrial membrane | 14 |
firing patterns | 14 |
health threats | 14 |
serum concentrations | 14 |
injury severity | 14 |
mice primed | 14 |
patients showed | 14 |
soluble antigen | 14 |
gut barrier | 14 |
using two | 14 |
accessory cells | 14 |
signaling cascade | 14 |
risk reduction | 14 |
selective pressure | 14 |
antioxidant defenses | 14 |
transplant recipients | 14 |
barrel cortex | 14 |
visual field | 14 |
using whole | 14 |
late stages | 14 |
term responses | 14 |
see also | 14 |
tumor development | 14 |
response efficacy | 14 |
estrogen receptor | 14 |
rats subjected | 14 |
normal controls | 14 |
human populations | 14 |
cells within | 14 |
phase protein | 14 |
kg bw | 14 |
elderly subjects | 14 |
stranded dna | 14 |
tyrosine hydroxylase | 14 |
lysosomal enzymes | 14 |
specific anti | 14 |
viral antigen | 14 |
nlrp inflammasome | 14 |
vaccine strains | 14 |
using different | 14 |
adenovirus vectors | 14 |
general hospital | 14 |
flow diagram | 14 |
association study | 14 |
tokyo university | 14 |
mediated activation | 14 |
memory formation | 14 |
genital tract | 14 |
structural changes | 14 |
cell dependent | 14 |
prime minister | 14 |
various pathogens | 14 |
neural mechanisms | 14 |
pig model | 14 |
among patients | 14 |
accumulating evidence | 14 |
natural history | 14 |
cytosolic sensing | 14 |
linear ubiquitin | 14 |
ammatory response | 14 |
antibiotic treatment | 14 |
cd memory | 14 |
igg levels | 14 |
structural protein | 14 |
strongly associated | 14 |
lymphatic system | 14 |
oxygen free | 14 |
helper type | 14 |
intradermal vaccination | 14 |
canine parvovirus | 14 |
interferon regulatory | 14 |
acid changes | 14 |
total number | 14 |
retinal ganglion | 14 |
also contribute | 14 |
emerging viral | 14 |
ns protein | 14 |
dawley rats | 14 |
case studies | 14 |
oxidative damage | 14 |
might play | 14 |
orthopaedic trauma | 14 |
blood monocytes | 14 |
protective response | 14 |
leading cause | 14 |
locus coeruleus | 14 |
significantly greater | 14 |
intracellular signaling | 14 |
ca signals | 14 |
large quantities | 14 |
technology agency | 14 |
social support | 14 |
endotoxin levels | 14 |
lps administration | 14 |
inactivated vaccines | 14 |
cyclic di | 14 |
inflammatory protein | 14 |
glutamate release | 14 |
derived neurotrophic | 14 |
protective responses | 14 |
memory cd | 14 |
i receptor | 14 |
genetic immunization | 14 |
powerful tool | 14 |
inner ear | 14 |
cultured hippocampal | 14 |
i cells | 14 |
respiratory viral | 14 |
i molecule | 14 |
disaster relief | 14 |
cd ctl | 14 |
contact tracing | 14 |
peptides corresponding | 14 |
antigenic peptide | 14 |
immune modulation | 14 |
functional analysis | 14 |
leukocyte antigen | 14 |
postsynaptic currents | 14 |
attenuated virus | 14 |
model antigen | 14 |
prevent infection | 14 |
may serve | 14 |
disease resistance | 14 |
evasion strategies | 14 |
crohns disease | 14 |
cardiac index | 14 |
embryonic day | 14 |
cell antigen | 14 |
prospective study | 14 |
trained immunity | 14 |
vascular smooth | 14 |
respiratory burst | 14 |
immune signaling | 14 |
nucleotide polymorphisms | 14 |
clinical data | 14 |
cellular processes | 14 |
conjugate vaccines | 14 |
virus infected | 14 |
effective mucosal | 14 |
mediated apoptosis | 14 |
activity may | 13 |
following injury | 13 |
adoptively transferred | 13 |
cell division | 13 |
cd lymphocytes | 13 |
mycobacterium bovis | 13 |
veterinary vaccines | 13 |
postoperative day | 13 |
virus ns | 13 |
supply chain | 13 |
additional studies | 13 |
state university | 13 |
public opinion | 13 |
expressed cd | 13 |
also express | 13 |
develop new | 13 |
sublingual immunization | 13 |
matching relationship | 13 |
immunosuppressive effects | 13 |
antibody titres | 13 |
genes related | 13 |
host gene | 13 |
current study | 13 |
effector mechanisms | 13 |
ca influx | 13 |
contact system | 13 |
immunological responses | 13 |
oxygen consumption | 13 |
dental university | 13 |
potent inhibitor | 13 |
also enhanced | 13 |
mice vaccinated | 13 |
coagulation cascade | 13 |
i production | 13 |
cellular mechanisms | 13 |
extracellular signal | 13 |
group received | 13 |
moral foundations | 13 |
induce immune | 13 |
protective antigens | 13 |
adenylate cyclase | 13 |
cultured cells | 13 |
viral quasispecies | 13 |
also demonstrated | 13 |
immune memory | 13 |
immune dysfunction | 13 |
proposed model | 13 |
double blind | 13 |
negative regulation | 13 |
genetic material | 13 |
studies suggested | 13 |
promoter regions | 13 |
coronavirus replication | 13 |
public crises | 13 |
i trial | 13 |
cell expansion | 13 |
experiments using | 13 |
higher concentrations | 13 |
virus may | 13 |
first week | 13 |
possible mechanism | 13 |
neutrophil recruitment | 13 |
study provides | 13 |
conformational change | 13 |
controlled release | 13 |
system dynamics | 13 |
severe cases | 13 |
antigenic variation | 13 |
infected macrophages | 13 |
goblet cells | 13 |
first two | 13 |
days following | 13 |
may allow | 13 |
vaccine group | 13 |
basic protein | 13 |
inactivated virus | 13 |
behavioral abnormalities | 13 |
present antigen | 13 |